IMVT — Immunovant, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1764013 ·
Last close
$33.21
Market Cap
$6.87B
52W High
$45.42
52W Low
$21.86
ADV30
1,456,337
Next earnings
2027-02-05
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -104,155,000 -97,246,000 760,967,000 722,274,000 104,022,000
Jun 2026 0 — -160,323,000 -153,224,000 852,490,000 797,798,000 117,102,000
Mar 2026 0 — -159,554,000 -147,856,000 957,014,000 902,110,000 104,422,000
Dec 2025 0 — -114,362,000 -110,635,000 1,052,392,000 994,525,000 66,257,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-395,004,000
Investing CF
$-8,000
Financing CF
$596,222,000
CapEx
$-201,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.56
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,995,599,000
Inventory
—
Receivables
$138,000
ST Investments
—
EBIT TTM
$-538,394,000
Pretax Income TTM
$-510,253,000
Interest Exp TTM
—
Analysts
16

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Mar 2026 0 -532,902,000 -505,606,000 957,014,000 104,422,000 852,592,000 -407,310,000
Mar 2025 0 -438,152,000 -413,840,000 776,222,000 68,775,000 707,447,000 -375,874,000
Mar 2024 0 -270,209,000 -259,336,000 666,365,000 48,608,000 617,757,000 -214,227,000
Mar 2023 0 -208,276,000 -210,960,000 405,838,000 43,344,000 362,494,000 -188,193,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
$-538,217,000
OpCashFlow TTM
—
Assets (Latest)
$852,490,000
Forward EPS
$-2.62

Max Pain — expiry 2026-12-18

max pain strike: $30.00 · spot: $33.17 · call oi: 13,435 · put oi: 1,639

Peers — same industry

TickerNameMarket CapLastDaily %
CGON CG Oncology, Inc. $7.00B $78.94 —
IBRX ImmunityBio, Inc. $6.66B $6.26 —
TWST Twist Bioscience Corp $7.43B $112.00 —
KOD Kodiak Sciences Inc. $6.33B $96.80 —
SRRK Scholar Rock Holding Corp $5.50B $45.08 —

News headlines (Yahoo Finance, 1h cache)

Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
2026-11-11 20:19 · Yahoo
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
2026-11-11 16:00 · Yahoo
Immunovant (IMVT) Q2 2027 Earnings Call Transcript
2026-11-10 02:03 · Yahoo
Immunovant, Inc. Q2 2027 Earnings Call Summary
2026-11-10 01:55 · Yahoo
Immunovant Stock What Changed After Arthritis Trial Success
2026-11-09 23:23 · Yahoo
What Immunovant (IMVT) Said on Its Q2 Earnings Call
2026-11-09 16:15 · Yahoo
Immunovant surges on trial results, earnings beat
2026-11-09 14:58 · Yahoo
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
2026-11-09 12:00 · Yahoo
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
2026-10-21 11:00 · Yahoo
Immunovant (IMVT) Stock Looks Stretched On Book Value Alone
2026-10-20 14:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.